Decavanadate effects in biological systems by Aureliano, M. & Gândara, Ricardo M. C.
JOURNAL OFwww.elsevier.com/locate/jinorgbio
Journal of Inorganic Biochemistry 99 (2005) 979–985
Inorganic
BiochemistryDecavanadate eﬀects in biological systems
Manuel Aureliano *, Ricardo M.C. Gaˆndara
CBME, Dept. Quı´mica e Bioquı´mica, FCT, Universidade do Algarve, 8005-139 Faro, Portugal
Received 27 January 2005; received in revised form 23 February 2005; accepted 25 February 2005
Available online 23 March 2005Abstract
Vanadium biological studies often disregarded the formation of decameric vanadate species known to interact, in vitro, with
high-aﬃnity with many proteins such as myosin and sarcoplasmic reticulum calcium pump and also to inhibit these biochemical
systems involved in energy transduction. Moreover, very few in vivo animal studies involving vanadium consider the contribution
of decavanadate to vanadium biological eﬀects. Recently, it has been shown that an acute exposure to decavanadate but not to other
vanadate oligomers induced oxidative stress and a diﬀerent fate in vanadium intracellular accumulation. Several markers of oxida-
tive stress analyzed on hepatic and cardiac tissue were monitored after in vivo eﬀect of an acute exposure (12, 24 h and 7 days), to a
sub-lethal concentration (5 mM; 1 mg/kg) of two vanadium solutions (‘‘metavanadate’’ and ‘‘decavanadate’’). It was observed that
‘‘decavanadate’’ promote diﬀerent eﬀects than other vanadate oligomers in catalase activity, glutathione content, lipid peroxidation,
mitochondrial superoxide anion production and vanadium accumulation, whereas both solutions seem to equally depress reactive
oxygen species (ROS) production as well as total intracellular reducing power. Vanadium is accumulated in mitochondria in par-
ticular when ‘‘decavanadate’’ is administered. These recent ﬁndings, that are now summarized, point out the decameric vanadate
species contributions to in vivo and in vitro eﬀects induced by vanadium in biological systems.
 2005 Elsevier Inc. All rights reserved.
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Vanadium was found in commercial ATP and redis-
covered for biology as a muscle inhibitor factor (MIF)
and Na+, K+-ATPase inhibitor [1–3]. Currently, vana-
dium is used as inhibitor of E1–E2 ion transport ATP-
ases [4] being a useful tool to mimics the transition
states of phosphoryl transfer reactions [5]. It has been
reported that vanadate reverses drug resistance [6,7], in-
creases glucose metabolism [8] and inﬂuences the activ-
ity of several enzymes, either inhibiting or stimulating
[9–11]. Recent data associated vanadium essentially to
the treatment of diabetes, due to its insulin mimetic0162-0134/$ - see front matter  2005 Elsevier Inc. All rights reserved.
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E-mail address: maalves@ualg.pt (M. Aureliano).properties [12–14] and to the prevention of animal car-
cinogens [15,16], however some studies of DCruz and
its collaborators have reported spermicidal and anti-
HIV activity of vanadium compounds [17].
Despite its toxicity at higher concentrations, vana-
dium is assumed to be an essential element for organ-
isms [18,19], although its biological role is far from a
clear identiﬁcation. In cells, oxovanadium(IV) species
are essentially the vanadium species present, even
though some of the interest in vanadium metallobio-
chemistry is probably due to the similarities between
the phosphate and vanadate chemistries in solution. In
that sense, a good number of the biochemical impor-
tance of vanadium is associated with the +5 oxidation
state (vanadate) [9]. However, in vanadium (+5) solu-
tions diﬀerent oligomeric (n = 1–10) vanadate anionic
species can occur simultaneously in equilibrium such
Fig. 1. 52.6 MHz 51V NMR spectra, at 22 C, of metavanadate (a and
b) and decavanadate (c) stock solutions, 50 mM in vanadium,
prepared from ammonium metavanadate: (a) pH 6.7; (b) pH 9.7 and
heated for 10 min; (c) pH 4.0. Vertical scale in (c) is ampliﬁed 4·. V1
and V2 NMR signals correspond, respectively, to monomeric
(VO34 ;HVO
2
4 and H2VO

4 ) and dimeric ðHV2O37 and H2V2O27 Þ
vanadate species irrespectively of the protonation state. V10A, V10B
and V10C are signals of vanadium atoms from the decameric ðV10O628 Þ
species.
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decameric (V10) species [20]. These vanadate species
are known to interact with many proteins besides aﬀect-
ing biological mechanisms [9–11,21,42].
Among the vanadate oligomers, decavanadate as
been referred of biochemical importance and is consid-
ered the major protein-bound species. In the last 10
years, reported decavanadate studies includes the possi-
bility to be used as a tool in the understanding of molec-
ular mechanism of muscle contraction [22], an inhibitor
of several ATPases such as P-type ATPases (E1/E2-
ATPases), ABC-ATPases and ribonucleases suggesting
that the V10 interaction with the proteins maybe favored
by the existence of an ATP binding site [21,23,24]. In
that sense, it is of particularly importance the study of
the structure of decavanadate formation in the presence
of organic compounds [25]. Moreover, decavanadate
modulates voltage-dependent Ca2+-active cation chan-
nel [26], mimics noradrenaline action [27] and induces
decavanadate reductase activity [28].
Vanadium is a heavy metal with increased environ-
mental circulation, resulting from various anthropo-
genic activities [29–31] and it is of great concern due
to its toxicity and accumulative behavior at speciﬁc tar-
get organs, such as the liver and kidney, inducing oxida-
tive damage, lipid peroxidation and changes in
haematological, reproductive and respiratory systems
[32–36]. Formation of reactive oxygen species (ROS) in-
duced by vanadium in biological systems may involve
Fenton-like reactions [34], vanadate bioreduction medi-
ated by reduced glutathione (GSH), ﬂavoenzymes or
nicotinamide adenine dinucleotide, reduced form
(NADH), and nicotinamide adenine dinucleotide phos-
phate, reduced form, (NADPH) oxidases [37–39] or
interaction with mitochondria [14].
In biological systems vanadium majority exists in
anionic and cationic forms, the most common ones
being vanadate ðH2VO4 Þ and oxovanadium(IV) (VO2+)
[40,41]. It is considered that almost 98% of vanadium
in cells is present as vanadium (+4) oxidation state
(oxovanadium(IV)). Besides, the intracellular concentra-
tion of vanadium (+5) (vanadate) is very low to vana-
date oligomers be formed. Those are probably the
reasons why in vivo toxicological studies of vanadate
oligomers eﬀects are scarce. However, it is proposed that
once formed the rate of decavanadate decomposition is
slow (half-life of h) enough to allow to study its eﬀects
not only in vitro, but also in vivo [42–45]. In fact, re-
cently reported studies demonstrated that, after 1 and
7 days of in vivo administration, decavanadate species
induces diﬀerent eﬀects, when compared to other oligo-
mers, on anti-oxidant enzymes, lipid peroxidation, sub-
cellular vanadium distribution and tissue damage in
liver, kidney and heart [43–45]. In the present review,
it is summarized these recent ﬁndings about the in vivo
decameric vanadate eﬀects besides the reported bio-chemical role on two energy transduction systems from
skeletal muscle namely, sarcoplasmic reticulum calcium
pump and myosin.2. Decameric species in vanadate solutions
Vanadium (V) solutions contain diﬀerent oligomeric
(n = 1–10) vanadate species in equilibrium, e.g., mono-
meric (V1), dimeric (V2), tetrameric (V4) and decameric
(V10) and in same cases, with diﬀerent states of proton-
ation and conformations [20]. Preparation of vanadate
solutions containing decameric species have been devel-
oped to study the interaction and/or eﬀects promoted by
these species in proteins [42,46–52].
Fig. 2. 52.6 MHz 51V NMR spectra, at 22 C, of a decavanadate stock
solution 100 mM in vanadium (10 mM in decavanadate), prepared
from sodium orthovanadate, after adjusting the pH to 4.0 and than to
7.0. V1 and V2 NMR signals correspond, respectively, to monomeric
ðVO34 ;HVO24 and H2VO4 Þ and dimeric ðHV2O37 and H2V2O27 Þ
vanadate species irrespectively of the protonation state. V10A, V10B
and V10C are signals of vanadium atoms from the decameric ðV10O628 Þ
species.
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aration of decavanadate solutions [53,54]. Twenty years
ago, in 1985, it was demonstrated that the mode of prep-
aration of vanadate solutions is determinant to obtain
only decameric species (Fig. 1). It should be noted that
often, vanadate solutions prepared from ammonium
metavanadate contain decameric species probably due
to an eventual acidiﬁcation of the medium. To avoid
the presence of decameric and other vanadate oligomers
the vanadate solutions should be heated for 10 min, at
pH 10 (Fig. 1(b)). More recently, it has been focus that
the denominated ‘‘decavanadate’’ stock solutions (con-
taining presumably only decameric species) are also of-
ten contaminated with other species. In fact, as
appraised by NMR spectroscopy, ‘‘decavanadate’’ stock
solution pH 4.0, 100 mM in total vanadium, contains
only 10 mM of decameric species since only signals from
decameric vanadate species are observed: V10A at
515 ppm, V10B at 500 ppm and V10C at 424 ppm
(Fig. 1(c)). When the pH is adjusted to 7.0, small
amounts of mono (V1) at 560 ppm, di (V2) at
574 ppm and tetrameric (V4) species at 578 ppm were
detected (Fig. 2). At room temperature, when this
‘‘decavanadate’’ solution is diluted into the reaction
medium in the concentration range normally used in ki-
netic studies (up to 5 mM in vanadium), the concentra-
tion of decameric vanadate increases linearly with total
vanadate [42]. At this experimental condition, the rate
of decomposition is slow (half-life of 5–15 h depending
on the medium) allowing studying the eﬀect of the deca-
meric species in the activity of enzymes. However, at
37 C, the disappearance of the 360 and 400 nm bands
ascribed to decameric species is faster with half-life be-
low 60 min [21].3. The iceberg phenomena: interactions and enzyme eﬀects
Often, the vanadate species variety is not accounted
for consideration in most biological studies, although
it is recognized that the individual species may diﬀer-
ently inﬂuence enzyme activities [9–11,21,42]. Therefore,
it is of primary importance to precisely characterize the
vanadate species and the interactions with the system
before attempting to understand the promoted eﬀects.
Allegorically, vanadate studies in biological systems
are comparable to the iceberg phenomena: there is an
invisible part, probably not the most interesting, but cer-
tainly the major.
The pioneer studies on the interaction between deca-
vanadate and proteins were performed with ribonucle-
ase, in 1973 [55]. These and other studies demonstrated
the decavanadate species as potentially responsible for
the eﬀects promoted in enzyme activities [9]. With sarco-
plasmic reticulum (SR) Ca2+-ATPase, decavanadate
interacts particularly with the E2 conformation of the en-
zyme [46,56], inducing crystallization of SR Ca2+-ATP-
ase dimmers [57,58], mediating photocleavage [50,51],
inhibiting ATP hydrolysis and Ca2+ accumulation [42],
proton ejection associated with Ca2+ translocation [52],
and both passive and active eﬄux of Ca2+ by the Ca2+
pump of sarcoplasmic reticulum [59].
SR Ca2+-ATPase is a transmembrane transport sys-
tem, which accumulates Ca2+ at expense of ATP split-
ting during the process of muscle relaxation. The
measurements of Ca2+ accumulation by the sarcoplas-
mic reticulum calcium pump reﬂect simultaneously the
uptake of Ca2+ through the pump and the Ca2+ eﬄux.
This eﬄux could be passive when not associated with
the pump activity or active when directly associated with
intrinsic reactions to the SR Ca2+ pump mechanisms.
Kinetic studies performed by radiometry shows that
the accumulation of Ca2+ by the sarcoplasmic reticulum
vesicles is strongly aﬀected by decavanadate [59].
SR vesicles loaded with radioactive Ca2+, sediment
by centrifugation and diluted into media containing eth-
ylenebis(oxyethylenenitrilo)tetraacetic acid (EGTA),
Ca2+ passively leaks through the ATPase. At this exper-
imental condition the ATPase works as a channel and
the oligomeric species of vanadate behave as natural li-
gands of the enzyme as observed before for ATPase
natural ligands such as Ca2+, Mg2+, K+, adenosine 5 0-
diphosphate (ADP), PO34 and Na
+. When SR vesicles
were diluted into media containing ADP and orthophos-
phate the Ca2+ eﬄux from the vesicles was strongly de-
pressed (85%) by 0.4 mM vanadate ‘‘decavanadate’’,
containing about 40 lM decameric species’’. Thus,
‘‘decavanadate’’ exert noticeable eﬀects when the eﬄux
of Ca2+ is associated with adenosine 5 0-triphosphate
(ATP) synthesis, being the active eﬄux of Ca2+ is almost
completely inhibited by ‘‘decavanadate’’ even for deca-
meric species concentration as low as 40 lM [59].
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ger aﬃnity for SR ATPase relatively to other oligomeric
species [46]. It was initially reported that decameric spe-
cies might bind to the ATPase at the vicinity of the
phosphate acceptor (351 aspartyl residue), thus blocking
the active site by preventing formation of the phos-
phoenzyme intermediate [47]. The decameric vanadate-
binding site to the enzyme has been referred as the
ATP binding site [47] or very close to it [51] in addition
to the binding site for monomeric species [47,48]. By
using small concentrations of ‘‘decavanadate’’ and
experimental conditions minimizing the contamination
from others species, it has been suggested that the deca-
meric species may bind to the SR ATPase after ATP
binding, whereas the appearance of monomeric species
induce decameric to compete with ATP [21]. It was ob-
served that by increasing the ‘‘decavanadate’’ concen-
tration SR calcium pump inhibition changes from
uncompetitive to non-competitive regarding ATP [21].
Decavanadate may bind at or near the nucleotide site
and involves Ser186 at the small cytosolic loop (A-do-
main) of the Ca2+-ATPase [60]. Moreover, we recently
veriﬁed that in the presence of 5 lM SR Ca2+-ATPase
the half-life of decameric vanadate, as low as 10 lM
decameric species (100 lM total vanadate), increases
from 5 to 18 h, at room temperature and pH 7.0, as ap-
praised by UV/vis at 400 nm. Therefore, apparently, the
disintegration of decameric vanadate follows a ﬁrst or-
der kinetic, independent of concentration, being pre-
vented by ATPases with high aﬃnity to V10.
Vanadate monomer, can act as a ground state or
transition state analogue of inorganic phosphate, which
has made this ion a valuable tool for studying enzyme-
catalyzed phosphotransferases and phosphohydrolases
reactions [5,9]. This is particular relevant for myosin
(M), the major ATPase of muscle, that is strongly inhib-
ited by vanadate. The head segment of myosin, called
subfragment 1 (S1), contains the binding sites for ATP
and actin, and is responsible for the ATPase activity
during the process of muscle contraction [61]. The bind-
ing of ATP reduces the aﬃnity of myosin for actin, and
the subsequent hydrolysis of ATP results in a ternary
complex between myosin, ADP and inorganic phos-
phate (Pi). The rate-limiting step of the ATP hydrolysis
is the release of Pi from myosin, which is accelerated by
the rebinding of actin. Vanadate inhibits myosin ATP-
ase activity by forming, in the absence of actin, a very
stable complex with MgADP that mimic either the tran-
sition state of hydrolysis or ADP Æ Pi intermediate state
[62].
Original ﬁndings that decameric also aﬀect the myo-
sin ATPase activity and that the inhibitory eﬀects are re-
stricted to some of the species were reported [22,63,64].
It has been proposed that V10 bind to myosin via the
‘‘back door’’ to form a more stable V10 myosin complex,
although the mechanism of interaction is still to be clar-ify. However, this V10 high aﬃnity-binding site produces
non-competitive inhibition of the actin stimulated S1-
ATPase activity, without causing dissociation of the
acto-S1 complex [22]. Additionally, it was demonstrated
unambiguously the residues undergoing photocleavage
on myosin by the decameric vanadate (V10) [65]. Two
putative binding sites one of higher aﬃnity located on
the 178–185 sequence (loop-P) which forms the consen-
sus ATP binding site of myosin and another one of
lower aﬃnity from residues 627–646 (loop-2), which
makes part of the actin-binding interface were proposed.
Suggested location of the myosin subfragment-1 high
aﬃnity binding site for decameric vanadate species
points to the S1 surface area bearing myosin segments
141–150, 180–190 and/or 706–726 which contains a total
of 13 positively charged amino acids (Lys + Arg) and
only 2 negatively charged amino acids (Asp + Glu)
(unpublished results). Another important result is that
V10 and V4 bind to the same protein binding site(s),
although its interactions are diﬀerently modulated by
the myosin natural ligands (ATP and actin). V10 appears
not to be aﬀected by the products release during ATP
hydrolysis, as shown by the NMR experiments. In addi-
tion, V10 has a greater aﬃnity for myosin binding sites
than V4 in the same way that, V4 has a greater aﬃnity
than the lower vanadate oligomers, which can be ex-
plained if electrostatic forces play an important role in
vanadate interaction with proteins that binds V10 such
as myosin, sarcoplasmic reticulum calcium pump and
other nucleotide binding enzymes [21,23,24,26–28]. In
that sense, V10 may contribute to the inhibition of ac-
tin-stimulated myosin ATPase activity, through binding
at the myosin phosphate loop. Therefore, even if V10 is
not likely to be present at signiﬁcant concentrations un-
der physiological conditions, it has revealed a useful bio-
chemical tool not only for the description of the location
and function of the phosphate binding sites on myosin,
but also for the molecular interpretation of actomyosin
interactions and consequently for muscle contraction
regulation [22,66].4. In vivo decavanadate eﬀects
As described above, several studies report that ‘‘deca-
vanadate’’ has a stronger inhibitory eﬀect on several en-
zymes, when compared to other vanadate oligomers.
Besides, decameric vanadate binding with speciﬁc pro-
teins may prevent its disintegration. However, only a
few studies consider the hypothesis of a possible eﬀect
of decavanadate at physiological conditions since, in
these conditions, vanadate is considered to be reduced
to oxovanadium(IV) and ‘‘decavanadate’’ concentration
is very low or is not present for long enough to induce
any eﬀects [67–70]. In order to relate the eﬀects observed
in vivo with the decavanadate present in solution, we
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observed that the half-life for decameric vanadate spe-
cies on ‘‘decavanadate’’ solution is about 10 h, at room
temperature. Our group have studied the in vivo eﬀect of
decavanadate, in vanadium accumulation in Halobatra-
chus didactylus [43,71] and in Spaurus aurata [72], in sev-
eral oxidative stress markers in the cardiac [43] and
hepatic tissues [71], in the metahaemoglobin reductase
activity [45] and in the histology of heart, kidney, and li-
ver of Halobatrachus didactylus [44], comparing the
injection of two vanadate solutions, ‘‘decavanadate’’
and ‘‘metavanadate’’, containing diﬀerent oligomeric
species.
In fact, when decavanadate was administered a diﬀer-
ent fate of intracellular vanadium accumulation is ob-
served. Seven days after decavanadate administration,
the vanadium content in the cytosolic fraction from car-
diac tissue was 4 times increased (p < 0.05) while no in-
crease was registered in metavanadate-administered
individuals, whereas both solutions increase up to 3
times the mitochondrial vanadium content [43]. In hepa-
tic tissue, decavanadate solution promotes a 5-fold in-
crease (p < 0.05) in the vanadium content of the
mitochondrial fraction 7 days after exposure while no
eﬀects were observed after metavanadate solution
administration [71]. Also, decavanadate induces diﬀer-
ent patterns of subcellular vanadium distribution in
blood plasma, red blood cells (RBC) and cardiac muscle
subcellular fractions of the ﬁsh Sparus aurata (gilthead
seabream), being vanadiummainly distributed in plasma,
before accumulated into the mitochondrial fraction
[72].
It was recently demonstrated that decavanadate in-
duce stronger eﬀects than metavanadates in the activity
of anti-oxidant enzymes and in lipid peroxidation of car-
diac tissue. The acute exposure to decavanadate in-
creases the oxidative stress, by depressing the activity
of anti-oxidant enzymes (catalase, superoxide dismutase
and glutathione peroxidase) and increasing the lipid per-
oxidation in the cardiac tissue of Halobatrachus didacty-
lus [43]. In the hepatic tissue, the overall oxidative stress
was not increased, but the mitochondrial superoxide an-
ion production and the lipid peroxidation was increased
after ‘‘decavanadate’’ solution administration [71]. It
was demonstrated that the administration of decameric
vanadate species induces diﬀerent eﬀects in hepatic and
cardiac oxidative stress markers when we compared with
other vanadate oligomers. All this data support the
hypothesis that mitochondria might be a target for deca-
meric vanadate species. Also, methaemoglobin reduc-
tase activity was aﬀected diﬀerently after the
administration of ‘‘decavanadate’’ or ‘‘metavanadate’’
solutions, metavanadate induced an increase of enzy-
matic activity, while in the presence of decavanadate
no signiﬁcant changes were observed [45]. Decavanadate
was reported to induce hypertrophy of the ventricle dueto a decrease in the percentage of myocardium occupied
by collagen ﬁbers [44].
Several suggestions on vanadate relation with ROS
were made so far; nonetheless more work is needed to
clarify whether vanadate speciation in vivo, its reduc-
tion, its action mechanisms and pathways could have
diﬀerent physiologic roles. One thing is becoming clear,
decavanadate seems to follow, not only in vitro but also
in vivo, diﬀerent pathways, with diﬀerent targets and ef-
fects than other vanadate oligomers. Decameric vana-
date is not normally considered biological studies, but
due to its stability at physiologic conditions, it may
not be completely disintegrated into other vanadate
oligomers before induces changes in several stress
markers.5. Conclusions
This review focuses the fact that decavanadate may
occur simultaneously with others oligomeric species in
vanadate solutions and therefore, it is important to
understand their contributions to vanadium toxicity.
Decavanadate species, present in vanadium (V) solu-
tions, contributed to the eﬀects induced by vanadate
on phosphohydrolases and ATPases such as the Ca2+-
pump of sarcoplasmic reticulum and myosin of skeletal
muscle. Decameric vanadate biological eﬀects are tight
related with these energy transduction systems, once
speciﬁc interactions and diﬀerent eﬀects were described.
Current studies are in progress in order to understand
the role of decavanadate in the modulation of muscle
contraction. Moreover, decavanadate in vivo intoxica-
tion clearly induces diﬀerent changes on oxidative stress
markers and lipid peroxidation than others oligomers.
Upon intoxication with decavanadate, the metabolism
of vanadium is aﬀected being mitochondria a potential
target. Although decameric vanadate is not normally
considered in biological studies, due to its stability at
physiologic pH, it is suggested that it may not com-
pletely fall apart into other vanadate oligomers before
induces changes in cell homeostasis, namely in several
stress markers. These results point out to the importance
of taking into account decavanadate in the evaluation of
vanadium biological eﬀects. It is believed that the pro-
gress in understanding the role and the contribution of
decavanadate to vanadium biological eﬀects may be use-
ful to gain a deeper knowledge in vanadium biochemis-
try (Fig. 3). Questions that remain to be addressed
include for instance: (i) How is decavanadate taken up
into cells? (ii) Can it be formed in intracellular medium?
(iii) Which are the molecular and subcellular targets of
V10 with physiological relevance? (iv) Is oxidative stress
induced by decavanadate due to its decomposition? (v)
Can ATPases be modulated by decavanadate? (vi)
How can decavanadate bind tightly to myosin and
Fig. 3. Scheme of the proposed cellular targets of decavanadate (V10): (1) V10 uptake through anionic channels; (2) V10 binding to membrane
proteins; (3) formation of V10 upon intracellular acidiﬁcation; (4) reduction of monomeric vanadate by antioxidant agents; (5) reduction of decameric
vanadate by enzymes; (6) binding of V10 to target proteins preventing its reduction; and (7) accumulation V10 into subcellular organelles such as
mitochondria. V10, decameric vanadate; V1, monomeric vanadate; E, enzyme; P, protein; AC, anionic channel; VO
2+, oxovanadium(IV) bound to a
bioligand.
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